See more : Guardian Pharmacy Services, Inc. (GRDN) Income Statement Analysis – Financial Results
Complete financial analysis of Zelira Therapeutics Limited (ZLDAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zelira Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bristol-Myers Squibb Company Ce (CELG-RI) Income Statement Analysis – Financial Results
- Pritika Auto Industries Limited (PRITIKAUTO.NS) Income Statement Analysis – Financial Results
- Cabasse Group (ALCG.PA) Income Statement Analysis – Financial Results
- Wiltrom Co., Ltd. (6767.TWO) Income Statement Analysis – Financial Results
- Aimer Co., Ltd. (603511.SS) Income Statement Analysis – Financial Results
Zelira Therapeutics Limited (ZLDAF)
About Zelira Therapeutics Limited
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.95K | 301.12K | 1.54M | 663.32K | 0.00 | 769.03K | 313.76K | 100.04K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 0.00 | 21.08M | 140.69K | 569.48K | 501.04K |
| Cost of Revenue | 84.67K | 3.52M | 939.05K | 228.22K | 275.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.85M | 70.66K | 178.19K | 141.29K |
| Gross Profit | 10.28K | -3.22M | 601.57K | 435.09K | -275.05K | 769.03K | 313.76K | 100.04K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 0.00 | 24.93M | 70.03K | 391.29K | 359.75K |
| Gross Profit Ratio | 10.83% | -1,068.03% | 39.05% | 65.59% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 118.25% | 49.78% | 68.71% | 71.80% |
| Research & Development | 2.81M | 1.34M | 1.40M | 2.08M | 3.69M | 2.33M | 1.79M | 668.41K | 14.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.34M | 3.06M | 6.08M | 4.49M | 1.97M | 1.25M | 397.37K | 1.35M | 456.94K | 207.75K | 180.00K | 214.56K | 443.35K | 242.51K | 490.56K | 507.34K | 59.75K | 1.20M | 675.35K | 372.46K | 245.36K |
| Selling & Marketing | 0.00 | -468.36K | 715.24K | 510.07K | 0.00 | 0.00 | 0.00 | 1.05M | 63.25K | 83.84K | 67.65K | 84.80K | 123.57K | 126.28K | 490.52K | 365.25K | 187.33K | 333.39K | 62.53K | 46.07K | 60.51K |
| SG&A | 1.34M | 2.59M | 6.08M | 4.49M | 1.97M | 1.25M | 397.37K | 1.35M | 456.94K | 207.75K | 180.00K | 214.56K | 443.35K | 242.51K | 490.56K | 507.34K | 59.75K | 1.20M | 675.35K | 372.46K | 245.36K |
| Other Expenses | -4.14M | -266.52K | 1.28M | 1.25M | 925.49K | 580.44K | 959.82K | 99.34K | -24.95K | 12.16K | -15.78K | -18.92K | -36.03K | 440.67K | -201.19K | 177.42K | -211.08K | -1.51M | -99.53K | 45.46K | 522.50K |
| Operating Expenses | 10.28K | 4.20M | 14.25M | 10.20M | 7.94M | 4.24M | 2.83M | 6.32M | 876.42K | 423.83K | 295.18K | 322.06K | 630.63K | 463.08K | 1.15M | 1.85M | 487.99K | 46.55M | 1.35M | 860.64K | 1.04M |
| Cost & Expenses | 5.50M | 7.71M | 15.19M | 10.42M | 7.94M | 4.24M | 2.83M | 6.32M | 876.42K | 423.83K | 295.18K | 322.06K | 630.63K | 463.08K | 1.15M | 1.85M | 487.99K | 42.70M | 1.42M | 1.04M | 1.18M |
| Interest Income | 309.00 | 134.00 | 10.60K | 723.00 | 8.60K | 90.14K | 138.57K | 67.72K | 2.73K | 11.59K | 20.74K | 29.13K | 28.70K | 29.44K | 58.77K | 129.43K | 22.62K | 64.67K | 95.38K | 117.06K | 129.78K |
| Interest Expense | 739.27K | 76.66K | 53.85K | 42.63K | 12.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 102.20K | 203.13K | 4.83K | 16.00 |
| Depreciation & Amortization | 479.04K | 545.22K | 588.54K | 474.26K | 275.05K | 3.32M | 2.37M | 2.44M | 161.10K | 0.00 | 336.00 | 5.22K | 13.95K | 11.54K | 16.97K | 16.81K | 0.00 | 3.15M | 62.05K | 72.28K | 27.02K |
| EBITDA | -35.52M | -5.65M | -11.77M | -8.03M | -7.51M | 0.00 | 0.00 | 0.00 | 0.00 | -423.83K | -294.84K | -316.84K | -616.67K | -451.54K | -1.10M | -1.53M | -487.99K | -19.94M | -1.22M | -234.56K | 1.45K |
| EBITDA Ratio | -37,409.90% | -2,280.68% | -764.05% | -1,210.92% | 0.00% | -551.13% | -901.40% | -6,321.81% | -292.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,955.02% | 0.00% | 0.00% | -94.60% | -867.45% | -41.19% | 0.29% |
| Operating Income | -5.94M | -7.41M | -12.36M | -8.51M | -7.00M | -4.24M | -2.83M | -6.32M | -876.42K | -423.83K | -295.18K | -322.06K | -630.63K | -463.08K | -686.56K | -1.55M | -487.99K | -23.09M | -1.28M | -306.84K | -25.56K |
| Operating Income Ratio | -6,253.93% | -2,461.74% | -802.25% | -1,282.41% | 0.00% | -551.13% | -901.40% | -6,321.81% | -292.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,004.55% | 0.00% | 0.00% | -109.55% | -911.55% | -53.88% | -5.10% |
| Total Other Income/Expenses | -30.80M | 233.40K | -26.27K | 248.29K | 352.62K | -262.65K | 622.83K | -3.75M | -108.21K | 23.75K | 4.96K | 10.22K | -7.33K | 470.11K | -1.00M | -18.72M | 22.62K | -16.54M | -203.13K | -4.83K | 652.26K |
| Income Before Tax | -36.74M | -7.41M | -12.41M | -8.55M | -7.02M | -3.57M | -1.73M | -6.16M | -898.64K | -400.08K | -290.22K | -311.84K | -637.96K | 7.03K | -1.69M | -20.27M | -465.37K | -38.16M | -1.49M | -311.67K | -25.58K |
| Income Before Tax Ratio | -38,692.98% | -2,461.31% | -805.75% | -1,288.84% | 0.00% | -463.94% | -551.32% | -6,154.83% | -299.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,928.45% | 0.00% | 0.00% | -181.04% | -1,055.93% | -54.73% | -5.10% |
| Income Tax Expense | 0.00 | -1.14M | 860.83K | 1.30M | 937.84K | -769.03K | -313.76K | -100.04K | -163.83K | 0.00 | -20.74K | -29.13K | -28.70K | -29.44K | 370.74K | 211.67K | -13.08M | -1.41M | -584.27K | -311.67K | -25.58K |
| Net Income | -36.57M | -5.57M | -11.95M | -8.55M | -7.02M | -3.57M | -1.73M | -6.16M | -898.64K | -400.08K | -290.22K | -311.84K | -637.96K | 7.03K | -1.69M | -20.27M | 12.61M | -38.16M | -901.34K | -311.67K | 0.00 |
| Net Income Ratio | -38,513.04% | -1,850.75% | -775.35% | -1,288.84% | 0.00% | -463.94% | -551.32% | -6,154.83% | -299.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,928.45% | 0.00% | 0.00% | -181.04% | -640.65% | -54.73% | 0.00% |
| EPS | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | -0.83 | -0.40 | -2.18 | -1.39 | -0.73 | -0.53 | -0.57 | -1.99 | 0.02 | -5.03 | -116.56 | 464.49 | -15.47K | -543.30 | -255.26 | 0.00 |
| EPS Diluted | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | -0.83 | -0.40 | -2.18 | -1.39 | -0.73 | -0.53 | -0.57 | -1.99 | 0.02 | -5.03 | -116.56 | 464.49 | -15.47K | -543.30 | -240.67 | 0.00 |
| Weighted Avg Shares Out | 11.35M | 10.07M | 8.04M | 6.63M | 4.85M | 4.31M | 4.31M | 2.83M | 646.55K | 551.24K | 551.24K | 551.24K | 320.42K | 335.85K | 335.86K | 173.91K | 27.16K | 2.47K | 1.66K | 1.22K | 1.09K |
| Weighted Avg Shares Out (Dil) | 11.35M | 10.07M | 8.04M | 6.63M | 4.85M | 4.31M | 4.31M | 2.83M | 646.55K | 551.24K | 551.24K | 551.24K | 320.42K | 335.85K | 335.86K | 173.91K | 27.16K | 2.47K | 1.66K | 1.30K | 1.09K |
Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is well placed to generate further growth in cash flow and revenue via its diversified income streams, with a suite of new products launched in H1 FY2022. The company generated quarterly cash receipts of $0.341...
Zelira Therapeutics receives A$1.292 million cash R&D tax incentive
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received a cash refund of A$1.292 million under the Australian Federal Government's Research and Development Tax Incentive Scheme. The funds received will be used to support Zelira's portfolio of products recently launched in global...
Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received US$250,000 of its upfront non-refundable, non-contingent licensing fee of US$1 million from DRCN Holdings LLC, with the remaining US$750,000 expected to be received in the first quarter of 2022. The global leader in...
Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF)'s open-label dose-escalation trial results in chronic non-cancer pain patients have been published in the peer-reviewed journal Pain And Therapy. The trial, undertaken by The St Vincent's Hospital Melbourne (SVHM) research team led by the coordinating...
Zelira Therapeutics expands into growing New Zealand cannabinoid-based medicines market
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is expanding into the growing New Zealand cannabinoid-based medicines market by way of a five-year exclusive distribution agreement with NUBU Pharmaceuticals. The agreement with NZ's largest medicinal cannabis distribution company furthers Zelira's global commercialisation strategy...
Zelira Therapeutics gets ethics green light for Phase 2a trial of sports injury cannabinoid
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), which develops clinically validated cannabis medications, has secured ethics approval for a Phase 2a clinical trial to assess the effectiveness of its licensed patented cannabinoid formulation, ZTL-106, in treating patients with chronic pain. Licensee Levin Health is sponsoring the trial at La Trobe University's Sport...
Zelira Therapeutics develops enhanced solid-form cannabinoid production method, signs foundational licensing deal
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has opened new pathways to develop pharmaceutical-grade cannabidiol capsules and tablets with its proprietary Enhanced Distillate Capture and Dissolution Matric (EDCDM) technology. The EDCDM technology solves a non-uniformity problem that causes cannabidiol distillate to separate from...
Zelira Therapeutics research-backed products behind its impressive growth
Zelira Therapeutics Ltd quarterly reads as a long list of highlights, which is testament to the work it is doing in the development of clinically validated cannabinoid medicines. The company has not only achieved a record for cash receipts, it...
Zelira Therapeutics gains substantial new US-based shareholder following US$5 million cap raise
Zelira Therapeutics Ltd has raised a total of US$5 million from a US-based family office fund to accelerate its growth initiatives. Zelira is a global leader in the research and development of clinically validated cannabinoid medicines and its initiatives include:...
Zelira Therapeutics set to launch suite of new cannabinoid-based products over FY22 and grow sales of existing products
Zelira Therapeutics Ltd's research and development (R&D) and commercialisation programs are expected to lead to the launch of a suite of new cannabinoid-based products over FY22. In FY21, the global medicinal cannabis company focused on expanding commercialisation activities and revenue...
Source: https://incomestatements.info
Category: Stock Reports